California Institute of Technology
Legal Disclaimer:
This website is not affiliated with, endorsed by, sponsored by, or connected in any way with the California Institute of Technology (Caltech) or any of its departments, researchers, or representatives.
The author of this website is acting independently to advocate for and support increased research attention, funding, and public awareness related to oncotripsy, with the goal of encouraging the timely advancement of clinical studies and the regulatory review process necessary for potential FDA approval.
Supporting Caltech’s pioneering oncotripsy research to offer gentler, targeted cancer treatments.
Why Oncotripsy?
Our Mission
We aim to accelerate clinical trials, making oncotripsy accessible as a safer alternative to chemo and radiation.
Innovative cancer treatment protocol at Caltech.
Why This Therapy works
Because it targets cancer cells precisely, sparing healthy tissue.
Mechanism of Action: Research indicates that oncotripsy, particularly using Low-Intensity Pulsed Ultrasound (LIPUS), breaks down the cytoskeleton of cancer cells by identifying specific, target-cell-matched frequencies.
Mathematical Modeling: Professors such as Michael Ortiz have developed, and continue to refine, mathematical models to predict how cell structures react to different acoustic waves.
Computational/Experimental Validation: Studies show that specific pulse durations (e.g., 30 ms) disrupt the actin ring in cancer cells. Research, in collaboration with the City of Hope Beckman Research Institute, has shown potential for targeting solid tumors, such as hepatocellular carcinoma (HCC), without affecting healthy tissues.
Viscoelastic Modeling: Subsequent studies investigated the influence of viscoelasticity and damping on the oncotripsy effect, establishing it as a form of mechanical cell fatigue.
This work is primarily driven by the Gharib Research Group and collaborators to advance it as a non-invasive treatment option.
The information regarding oncotripsy is based on current research and clinical trials. Its full benefits, limitations, and side effect profile in broad clinical use are still being determined.
Support Trials
Your donations accelerate clinical research progress.
The development of cancer treatments that can selectively destroy malignant cells without harming surrounding healthy tissue remains a central objective in oncology. Traditional ultrasound tumor ablation systems achieve this by concentrating high-intensity waves to generate localized heating and mechanical disruption within tumors. However, this approach can damage healthy tissue as well as cancerous tissue, requiring precise targeting to avoid injury to critical structures.
Recent computational research indicates that low-intensity ultrasound delivered at specific resonance frequencies may be capable of lysing cancer cells while leaving normal cells unaffected. This phenomenon, known as “oncotripsy,” is based on the induction of resonant oscillations in cellular membranes that lead to membrane rupture. Because these resonance frequencies depend on the mechanical properties of cells, they differ between cancerous and non-cancerous cells, making malignant cells selectively vulnerable to certain ultrasound frequencies.
Although computational models have demonstrated the potential for cell-specific destruction in hepatocellular carcinoma (HCC) without damaging healthy hepatocytes, this concept has not yet been validated in biological tissue.
Our research seeks to evaluate the feasibility of ultrasound-based oncotripsy as a therapeutic approach for HCC. Using both in vitro and in vivo models, we aim to assess its effectiveness and specificity in disrupting cancerous cells. The findings from this work will help determine the broader potential of oncotripsy as a treatment for HCC and other solid tumors.
Information here is from the Gharib Research Group Web Page. We thank them for this insight.